Drugs / [18F]-Fluorocellobiose
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07704333 | Jul 2026 → Jun 2029 expected | Zygomycosis, aspergillosis | National Institutes of Health Clinical Center (CC) | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]-Fluorocellobiose | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07704333 ↗ |
| Known as | [18F]FCB | “[18F]-Fluorocellobiose ([18F]FCB)” NCT07704333 ↗ |
| Modality | Diagnostic / imaging agent | “novel PET radiopharmaceutical” NCT07704333 ↗ |
| Route | Intravenous | “A thin tube called a catheter will be inserted into a vein in the arm. The study tracer will be given through the catheter.” NCT07704333 ↗ |